 | Up a level |
Hyman, David M., Tran, Ben, Paz-Ares, Luis, Machiels, Jean-Pascal, Schellens, Jan H., Bedard, Philippe L., Campone, Mario, Cassier, Philippe A., Sarantopoulos, John, Vaishampayan, Ulka, Chugh, Rashmi, Mahipal, Amit, Lockhart, A. Craig, Sessa, Cristiana, Zander, Thomas, Ng, Matthew, Curigliano, Giuseppe 
ORCID: 0000-0003-1781-2518, Bendiske, Jennifer, Chen, Xueying, Choudhury, Somesh, Graus-Porta, Diana, Lewis, Nancy, Perez Garcia, Jose Manuel and Jose de Miguel-Luken, Maria
(2019).
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations.
JCO Precis. Oncol., 3.
ALEXANDRIA:
AMER SOC CLINICAL ONCOLOGY.
ISSN 2473-4284
Sequist, Lecia V., Cassier, Phillippe, Varga, Andrea, Tabernero, Josep, Schellens, Jan H., Delord, Jean-Pierre, LoRusso, Patricia, Camidge, D. Ross, Hidalgo Medina, Manuel, Schuler, Martin, Campone, Mario, Tian, G. Gary, Wong, Steven, Corral, Jesus, Isaacs, Randi, Sen, Suman K., Porta, Diana Graus, Kulkarni, Swarupa G., Lefebvre, Caroline and Wolf, Juergen (2014). Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res., 74 (19). PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1538-7445